HSBC Increases Gilead Sciences (NASDAQ:GILD) Price Target to $133.00

Gilead Sciences (NASDAQ:GILD) had its target price upped by investment analysts at HSBC from $110.00 to $133.00 in a research note issued to investors on Wednesday,MarketScreener reports. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. HSBC’s target price indicates a potential upside of 11.81% from the stock’s previous close.

Other analysts have also issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a report on Friday, October 31st. Rothschild & Co Redburn boosted their target price on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Sanford C. Bernstein reissued an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Scotiabank assumed coverage on Gilead Sciences in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price objective on the stock. Finally, Daiwa Capital Markets lifted their target price on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $130.96.

Gilead Sciences Trading Down 1.8%

GILD stock opened at $118.96 on Wednesday. The firm has a fifty day moving average price of $121.28 and a 200 day moving average price of $115.53. Gilead Sciences has a fifty-two week low of $88.57 and a fifty-two week high of $128.70. The firm has a market cap of $147.59 billion, a PE ratio of 18.44, a price-to-earnings-growth ratio of 0.67 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business’s revenue was up 3.0% on a year-over-year basis. During the same period last year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts anticipate that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Transactions at Gilead Sciences

In related news, EVP Deborah H. Telman sold 53,646 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the transaction, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. This represents a 55.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 135,757 shares of company stock valued at $16,616,127. 0.27% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GoalVest Advisory LLC increased its holdings in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the third quarter valued at approximately $26,000. Activest Wealth Management grew its holdings in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences in the second quarter worth about $27,000. Finally, Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences during the second quarter valued at $30,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.